Naglazyme (galsulfase) Coverage Criteria for Mucopolysaccharidosis VI
Customize your policy alerts
Sign up for Molina Healthcare Policy C28288-A alerts
Get alerted when Policy C28288-A changes without checking for updates manually.
Monitor payer policy activity
Coverage and prior authorization requirements for intravenous Naglazyme (galsulfase) to treat mucopolysaccharidosis VI, including clinical, documentation, dosing, and administration requirements.
The policy revision history identifies revisions to required medical information, continuation-of-therapy criteria, and quantity requirements.
The policy was revised from the retired enzyme replacement therapy policy for lysosomal storage disorders involving MPS I and MPS VI.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.